OBJECTIVES: This study sought to determine the independent association of renal insufficiency with cardiovascular risk among women with known coronary heart disease (CHD). BACKGROUND: Although patients with end-stage renal disease and proteinuria are at high risk for cardiovascular events, little is known about the cardiovascular risk associated with moderate renal insufficiency. METHODS: The Heart and Estrogen/progestin Replacement Study (HERS) was a clinical trial among 2,763 women with coronary disease who were randomized toconjugated estrogen plus progestins or identical placebo and followed for a mean of 4.1 years. Women were categorized as having normal renal function (creatinine < 1.2 mg/dl; n = 2,012), mild renal insufficiency (1.2 mg/dl to 1.4 mg/dl; n = 567) and moderate renal insufficiency (>1.4 mg/dl; n = 182). We examined the independent association of renal function with incident cardiovascular events including CHD death, nonfatal myocardial infarction, hospitalization for unstable angina, stroke and transient ischemic attacks. RESULTS: Compared with women with normal renal function, those with mild and moderate renal insufficiency were older, more likely to be black, have a history of hypertension and diabetes and have higher serum levels of triglycerides and lipoprotein(a). After multivariate adjustment, both mild (relative hazards [RH] = 1.24; 95% confidence interval [CI]: 1.0 to 1.5) and moderate renal insufficiency (RH = 1.57; 95% CI: 1.2 to 2.1) were independently associated with increased risk for cardiovascular events compared with women with normal renal function. CONCLUSIONS: Renal insufficiency is an independent risk factor for cardiovascular events in postmenopausal women with known coronary artery disease. Renal function may add helpful information to CHD risk stratification.
RCT Entities:
OBJECTIVES: This study sought to determine the independent association of renal insufficiency with cardiovascular risk among women with known coronary heart disease (CHD). BACKGROUND: Although patients with end-stage renal disease and proteinuria are at high risk for cardiovascular events, little is known about the cardiovascular risk associated with moderate renal insufficiency. METHODS: The Heart and Estrogen/progestin Replacement Study (HERS) was a clinical trial among 2,763 women with coronary disease who were randomized to conjugated estrogen plus progestins or identical placebo and followed for a mean of 4.1 years. Women were categorized as having normal renal function (creatinine < 1.2 mg/dl; n = 2,012), mild renal insufficiency (1.2 mg/dl to 1.4 mg/dl; n = 567) and moderate renal insufficiency (>1.4 mg/dl; n = 182). We examined the independent association of renal function with incident cardiovascular events including CHD death, nonfatal myocardial infarction, hospitalization for unstable angina, stroke and transient ischemic attacks. RESULTS: Compared with women with normal renal function, those with mild and moderate renal insufficiency were older, more likely to be black, have a history of hypertension and diabetes and have higher serum levels of triglycerides and lipoprotein(a). After multivariate adjustment, both mild (relative hazards [RH] = 1.24; 95% confidence interval [CI]: 1.0 to 1.5) and moderate renal insufficiency (RH = 1.57; 95% CI: 1.2 to 2.1) were independently associated with increased risk for cardiovascular events compared with women with normal renal function. CONCLUSIONS:Renal insufficiency is an independent risk factor for cardiovascular events in postmenopausal women with known coronary artery disease. Renal function may add helpful information to CHD risk stratification.
Authors: Rajesh Mohandas; Mark Segal; Titte R Srinivas; B Delia Johnson; Xuerong Wen; Eileen M Handberg; John W Petersen; George Sopko; C Noel Bairey Merz; Carl J Pepine Journal: Am Heart J Date: 2015-01-06 Impact factor: 4.749
Authors: J R Cassuto; P P Reese; S Sonnad; R D Bloom; M H Levine; K M Olthoff; A Shaked; A Naji; P Abt Journal: Am J Transplant Date: 2010-11 Impact factor: 8.086
Authors: Stephen Zewinger; Thimoteus Speer; Marcus E Kleber; Hubert Scharnagl; Rainer Woitas; Philipp M Lepper; Karolin Pfahler; Sarah Seiler; Gunnar H Heine; Winfried März; Günther Silbernagel; Danilo Fliser Journal: J Am Soc Nephrol Date: 2014-03-07 Impact factor: 10.121
Authors: Anh L Bui; Ronit Katz; Bryan Kestenbaum; Ian H de Boer; Linda F Fried; Joseph F Polak; Bruce A Wasserman; Mark J Sarnak; David Siscovick; Michael G Shlipak Journal: Am J Kidney Dis Date: 2008-09-27 Impact factor: 8.860
Authors: Germaine Wong; Andrew Hayen; Jeremy R Chapman; Angela C Webster; Jie Jin Wang; Paul Mitchell; Jonathan C Craig Journal: J Am Soc Nephrol Date: 2009-04-30 Impact factor: 10.121